Skip to content

Psilocybin: all studies

Page 105 of 439: studies 1,041 to 1,050 of 4,389, newest first. Back to the psilocybin overview

Research

The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation

Genes January 29, 2024 Esmaeel Ghasemi Gojani, Bo Wang, Olga Kovalchuk et al. 11 citations

Serotonin emerges as a pivotal factor influencing the growth and functionality of β-cells. Psilocybin, a natural compound derived from mushrooms of the Psilocybe genus, exerts agonistic effects on the serotonin 5-HT2A and 5-HT2B receptors, thereby mimicking serotonin’s behavior. This study investigates the potential impacts of psilocybin on β-cell viability, dedifferentiation, and function...

DOI: 10.3390/genes15020183 (opens in new tab) Psilocybin Viability assay Cell biology Hallucinogen

The Effects of Psilocybin on Lipopolysaccharide-Induced Inflammation in THP-1 Human Macrophages

Psychoactives January 28, 2024 Esmaeel Ghasemi Gojani, Bo Wang, Dongping Li et al. 12 citations

Psilocybin, an innate compound produced by mushrooms belonging to the Psilocybe genus, is primarily known for its agonistic effects on the serotonin 5-HT2A receptor. This receptor’s functioning is involved in many neurological processes. In the context of this research, our primary aim was to comprehensively investigate the influence of psilocybin as a serotonin receptor agonist on the...

DOI: 10.3390/psychoactives3010004 (opens in new tab) Psilocybin Thp1 cell line Lipopolysaccharide Inflammation

Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial.

BMC Psychiatry January 26, 2024 Laetitia Vanderijst, Felix Hever, Anne Buot et al. 11 citations

A significant number of individuals with alcohol use disorder remain unresponsive to currently available treatments, which calls for the development of new alternatives. In parallel, psilocybin-assisted therapy for alcohol use disorder has recently yielded promising preliminary results. Building on extant findings, the proposed study is set to evaluate the feasibility and preliminary clinical...

DOI: 10.1186/s12888-024-05502-y (opens in new tab) Full text (opens in new tab) Psychedelic therapy Psilocybin-assisted therapy Serotonergic psychedelics Clinical trials +3

Psilocybin and eugenol prevent DSS-induced neuroinflammation in mice

Biocatalysis and Agricultural Biotechnology January 25, 2024 Timur Zanikov, Marta Gerasymchuk, Gregory Ian Robinson et al. 10 citations

Neuroinflammation has emerged as a central pathology common to several acute and chronic brain diseases. Recent studies have displayed the anti-inflammatory properties of naturally occurring compounds derived from mushrooms and plants could potentially reduce neuroinflammation and disease progression. In this study, we aimed to investigate the impact of psilocybin and eugenol, as well as their...

DOI: 10.1016/j.bcab.2024.103033 (opens in new tab) Psilocybin Neuroinflammation Eugenol Pharmacology +4

Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey

Palliative Medicine January 22, 2024 Louis Plourde, Sue-Ling Chang, Houman Farzin et al. 22 citations

Background: Internationally, there is a growing interest in the potential benefits of psilocybin-assisted therapy to treat existential distress at the end of life. However, the social acceptability of this therapy is not yet well known. Aim: This study assesses the social acceptability of the medical use of psilocybin to treat existential distress at the end of life. Design: An online survey...

DOI: 10.1177/02692163231222430 (opens in new tab) Psilocybin Palliative care End-of-life care Distress +4

Psilocybin biphasically modulates cortical and behavioral activity in mice

bioRxiv (Cold Spring Harbor Laboratory) January 20, 2024 Adam T. Brockett, Nikolas A. Francis 1 citation preprint

SUMMARY Psilocybin is a serotonergic psychedelic believed to have therapeutic potential for neuropsychiatric conditions. Despite well-documented prevalence of perceptual alterations, hallucinations, and synesthesia associated with psychedelic experiences, little is known about how psilocybin affects sensory cortex or alters the activity of neurons in awake animals. To investigate, we conducted...

High-resolution tracking of unconfined zebrafish behavior reveals stimulatory and anxiolytic effects of psilocybin

Molecular Psychiatry January 17, 2024 Dotan Braun, Ayelet M Rosenberg, Elad Rabaniam et al. 32 citations

Abstract Serotonergic psychedelics are emerging therapeutics for psychiatric disorders, yet their underlying mechanisms of action in the brain remain largely elusive. Here, we developed a wide-field behavioral tracking system for larval zebrafish and investigated the effects of psilocybin, a psychedelic serotonin receptor agonist. Machine learning analyses of precise body kinematics identified...

Abstract C001: A pilot study of palliadelic treatment with psilocybin to reduce psychological distress and improve quality of life in patients with advanced pancreatic adenocarcinoma

Cancer Research January 16, 2024 Kelsey Klute, Lou Lukas, Soonjo Hwang et al. 2 citations

Abstract Background: Psychological distress is a common reaction to a cancer diagnosis and its treatment. Distress impacts quality of life, adherence to treatment, decision making and survival. Patients with pancreatic adenocarcinoma (PDAC) experience exceptionally high rates of psychological distress, most commonly depression, anxiety and suicidality. Psilocybin, a serotonergic psychedelic...

MicroRNAs underlying the antidepressant effect of psilocybin – Establishing an nCounter pipeline for microRNA-quantification in the pig brain

Research Square January 12, 2024 Erik Kaadt, Rolf Søkilde, Hanne D. Hansen et al. preprint

Abstract Novel treatment strategies are needed to overcome some of the current challenges related to treatment resistance and treatment latency within the psychiatric field. Recently, psilocybin has shown promise as a novel treatment of major depressive disorder. A single dose of psilocybin is associated with lasting changes in personality and mood. In parallel, various studies have indicated...

Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical study

January 11, 2024 Link Swanson, Sophia Jungers, Ranji Varghese et al. 1 citation preprint

In visual perception, an effect known as surround suppression occurs wherein the apparent contrast of a center stimulus is reduced when it is presented within a higher-contrast surrounding stimulus. Many key aspects of visual perception involve surround suppression, yet the neuromodulatory processes involved remain unclear. Psilocybin is a serotonergic psychedelic compound known for its robust...

DOI: 10.31234/osf.io/5rm62 (opens in new tab) Psilocybin Visual hallucination Stimulus psychology Hallucinogen +7